Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.60 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802298 | 0.80 | GRIA1 (0.57) | GRIA1GRIA2GRIA3GRIA4KIF11 | |
| SCHEMBL4118733 | 0.76 | GRIA1 (0.46) | GRIA1GRIA2GRIA3GRIA4CES2 | |
| SCHEMBL1410369 | 0.75 | GRIA1 (0.48) | GRIA1GRIA2GRIA3GRIA4CES2 | |
| SCHEMBL8184247 | 0.74 | GRIA1 (0.54) | GRIA1GRIA2GRIA3GRIA4KIF11 | |
| SCHEMBL28876830 | 0.74 | ALDH1A1 (0.62) | GRIA1GRIA2GRIA3GRIA4CES2 | |
| SCHEMBL18003321 | 0.72 | GRIA1 (0.46) | GRIA1GRIA2GRIA3GRIA4KIF11 | |
| SCHEMBL9705638 | 0.72 | GRIA1 (0.45) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL4922867 | 0.71 | GRIA1 (0.44) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL29935776 | 0.69 | KIF11 (0.49) | GRIA1GRIA2GRIA3GRIA4KIF11 | |
| SCHEMBL2749018 | 0.69 | ALDH1A1 (0.40) | GRIA1GRIA2GRIA3GRIA4CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | GRIA1 744/4885GRIA2 1025/4885GRIA3 1327/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | GRIA1 744/4885GRIA2 1025/4885GRIA3 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.